ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1558

Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis

Birju D. Bhatt1, J. Lynn Palmer2, Jeffrey R. Curtis3, Sathya Velkuru4 and Joel Kremer5, 1Medicine, div-of Rheumatology, Albany Medical College, Albany, NY, 2Corrona Research Foundation, Albany, NY, 3Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 4Medicine, Albany Medical College, Albany, NY, 5Albany Medical College and the Center for Rheumatology, Albany, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologic drugs, Cardiovascular disease, hypertension, psoriasis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  

Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN) in patients with psoriasis has been well documented; about 30% of all psoriatic arthritis (PsA) patients have HTN. Treatment of PsA has also been shown to improve certain cardiovascular risks. We hypothesized that blood pressure was related to PsA disease activity. We also evaluated the relationship between PsA and blood pressure as it relates to initiation of TNF inhibitors (TNFi).

Methods:  

We utilized the CORRONA database and examined patients with PsA from March 2013 to January 2017. Descriptive statistics were used to summarize patient demographic and clinical data at baseline (first visit in CORRONA database). An analysis of variance was made to determine associations between 3 categories of MD-defined psoriatic body surface area (BSA) and systolic blood pressure (SBP) and diastolic blood pressure (DBP). Spearman correlations were made between continuous values of systolic or diastolic blood pressure and BSA and clinical disease activity index (CDAI) using all visits. We also looked at changes in SBP or DBP between visits correlated with changes in CDAI in those who were initiated on TNFi while they were in the registry. LOESS curves were generated to visualize relationships between variables. 

Results:  

1481 patients with PsA were identified, who had a total of 6109 registry visits. When body surface area (BSA) of psoriasis was categorized into ² 2%, 3-10% and >10% in analysis of variance, SBP was higher with increased BSA (p=0.0048, F=7.26, r2=0.025). DBP was also higher with an increased BSA (p<0.0001, F=15.28, r2=0.005). SBP was positively correlated with CDAI (p=0.0057, r=0.037), as was DBP (p=0.0012, r=0.044). The association between SBP change and CDAI change in those who were initiated with a TNFi showed an overall decrease in SBP that was not statistically significant (p=0.26, r= -0.041). In addition, DBP change and CDAI change in those who initiated a TNFi also showed a non-statistically significant decrease (p=0.13, r= -0.054).

Conclusion:  

In patients with PsA, there was a significant positive relationship between blood pressure and both psoriasis BSA and joint disease activity, measured by CDAI. We also conclude that clinically, the initiation of TNFi did decrease blood pressure, but the decrease was not significant. We believe that this is the first study to look at relationships between the initiation of TNFi treatment and blood pressure in PsA patients.

Description: The SGPlot Procedure

Description: The SGPlot Procedure


Disclosure: B. D. Bhatt, None; J. L. Palmer, None; J. R. Curtis, AbbVie, Amgen, BMS, Janssen, Pfizer, Roche/Genentech, Corrona, UCB, 2,AbbVie, Amgen, BMS, Janssen, Pfizer, Roche/Genentech, Corrona, UCB, 5,University of Alabama at Birmingham, 3; S. Velkuru, None; J. Kremer, Corrona, LLC, 1,Corrona, LLC, 3,AbbVie, Amgen, BMS, Genentech, Lilly, Regeneron, Sanofi, Pfizer, 5,AbbVie, Genentech, Lilly, Novartis, Pfizer, 2.

To cite this abstract in AMA style:

Bhatt BD, Palmer JL, Curtis JR, Velkuru S, Kremer J. Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/changes-in-blood-pressure-with-tnf-inhibitors-for-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-blood-pressure-with-tnf-inhibitors-for-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology